# **The Effects of Long COVID on Thai Teenagers**

Chantisa Boontia<sup>1</sup>, Jarut Wongwachirapan<sup>2</sup>, Nalinnipha Kaewsuwan<sup>3</sup>, Taksaporn Lapsirisopa<sup>4</sup>, Tanyarat Anotaipaiboon<sup>5</sup>, Suthara Chuayprasatwatana<sup>6</sup>, Watsaphon Watcharinthada<sup>7</sup>

<sup>1</sup>Samsenwittayalai School, Bangkok, Thailand
 <sup>2</sup>Princess Chulabhorn Science High School, Trang, Thailand
 <sup>3</sup>Samutprakan School, Samutprakarn, Thailand
 <sup>4</sup>Saparachinee Trang School, Trang, Thailand
 <sup>5</sup>Surawiwat School, Suranaree University of Technology, Nakhonratchasima, Thailand
 <sup>6</sup>The Demonstration School of Silpakorn University, Nakhon Pathom, Thailand
 <sup>7</sup>Buranarumluk, Trang, Thailand

Corresponding Author: Chantisa Boontia

DOI: https://doi.org/10.52403/ijshr.20220744

#### ABSTRACT

The post-COVID-19 condition, also known as the Long COVID syndrome, was first widely acknowledged in the scientific and medical worlds. Since it affects COVID-19 survivors at all disease severity levels, including younger individuals, children, and those who are not in hospitals, this illness is poorly understood. Presently, there is a limitation to the definition of the post-COVID condition. This study would fill in this gap by surveying the most common symptoms among Thai teenagers (10-24). This data is gathered by the online survey: Google Form and statistically analyzed through percentages. Consequently, the majority of symptoms are aches and pains (37.037%), (31.579%), asymptomatic depression (18.324%), and bedridden symptoms (6.324%) as a result of the prolonged quarantine. In terms of drug complications, the majority of respondents had none (89.330%), acid reflux (4.715%), and glycemic instability (1.489%). In terms of physical health effects following illness, the majority of respondents reported symptoms such as shortness of breath (30.615%), fatigue (27.227%), chronic cough (13.802%), insomnia (11.543%), and so on. This study shows that Long COVID has an impact on the respondents' daily lives at levels 1-10 on level 7 (15.960%), level 5 (13.965%), and level (13.965%).

*Keywords:* Long COVID, Thai teenager, Thailand

#### **INTRODUCTION**

Coronavirus disease 2019 (COVID-19) has spread significantly worldwide and many people are suffering from this pandemic due to the effects of physical health, mental health, and economic system in their own countries. (Lateh et al., 2021) This respiratory infection was caused from the SARS-CoV-2 virus which initially emerged in Wuhan, China in December 2019 by the animal reservoir (Lateh et al., 2021). Importantly, Coronaviruses severely digest through the respiratory system and SARS-CoV-2 is uninterruptedly changing. (Tang et al., 2020) In addition, because of airborne dispersion, small droplets or contact with infected surfaces are perhaps the most common ways for this disease to transmit between person to person.

Common symptoms of COVID-19 include fever, dry cough, fatigue, and loss of smell and taste. There are a variety of different symptoms of COVID-19 ranging from no symptoms to severe illness. After the first outbreak occurred in China, the World Health Organization (WHO) declared a Public Health Emergency of International Concern (PHEIC). Due to the COVID-19 pandemic, the number of deaths and infections increased around the world. On 13 January 2020, COVID-19 in Thailand was the first recorded case outside of China. Meanwhile, the number of Thai citizens who died from this disease was recently reported at 29,472 on 15 May 2022. (Prevention, 2022; Publishing, 2022)

However, this pandemic can be prevented by keeping distance between people, getting vaccinated, and wearing a face mask to prevent infection and avoid spreading. In Thailand, the government has been motivating Thai citizens with Fit from Home (FFH) which is a guide published by Thai Health Promotion Foundation. This helps citizens to handle this recent pandemic and boost their immune system by doing physical activities. (Hammami, some Harrabi, Mohr, & Krustrup, 2020; Widyastaria, Katewongsa, Saonuam, Haematulin, & Wongsingha, 2021)

Patients infected with COVID-19. After being infected, most patients will have ongoing conditions related to COVID. Which is called the Long COVID-19 symptom. At first it may be a symptom that most people do not know and do not pay attention to, but the symptoms become more involved in daily life. (Taribagil, Creer, & Tahir, 2021)

From the current situation have found symptoms or complications, whether physical psychological and symptoms caused by complications from medication while undergoing treatment for COVID-19. Many respected research institutes have recognized it as a result of COVID-19 infection, known as Long COVID-19 at the time. Studies have shown that Long COVID-19 symptoms can affect COVID-19 patients ranging from mild to severe symptoms to many organs including various systems in the body such as the respiratory system, cardiovascular system, nervous system, digestive system, and musculoskeletal system. (Crook, Raza, Nowell, Young, & Edison, 2021)

The primary symptoms during Long COVID-19 with the most common physical

complications are fatigue, difficulty breathing, muscle pain, joint pain, headache, cough, and chest pain. Some patients have changes in smell, taste and some diarrhea. Symptoms are caused by difficulty from the medication during treatment. There may be side effects caused by receiving drugs such as steroids. Symptoms that may have been seen after returning home such as stomach pain and appear to be suffering from acid reflux. Also, unstable sugar or diabetes. (William Ericson-Neilsen)

The mental health symptoms, the unpredictability of Long COVID-19 will affect patients in many areas, including social and schooling. Which tends to cause psychological distress Research has shown that up to a third of people may experience anxiety and mood disorders six months after their first COVID-19 infection. There is evidence to suggest the increasing mental health impact of the epidemic on patients who have been exposed to COVID-19. The outbreak continues to spread throughout Including various places. educational institutions, what happened more than raising awareness or approving holidays for people infected with COVID-19 is anxiety and mood swings which have always been a part of life. Although, the COVID-19 pandemic has driven these things into the spotlight. Studies have found that the most common primary mental health symptoms associated with Long COVID-19 were anxiety. Depression or other mood changes, trouble concentrating, or memory. Difficulty dread of sleeping illness have traumatic memories of health feelings of loneliness, (Katewongsa et al., 2021) symptoms usually appear 4 to 12 weeks after exposure, which can improve or worsen over time. Or there is a recurrence again. (Services; Sivan & Taylor, 2020)

The symptoms associated with SARS-CoV-2 infection in young people are rarely unusual or severe. Although the risk of contracting COVID-19 in the short term is low, that does not mean there are no longterm symptoms of SARS-CoV-2 or Long COVID-19 infection. Long COVID-19 symptoms, most studies have been done in adults. More than half of those admitted to hospital have had long-term residual symptoms of COVID-19, and little information about long-term COVID in is currently available. young people Symptoms Including impact on life this survey research aims to explore the duration, symptoms and impacts that occur in the Thai young population. (Fainardi et al., 2022)

studies Several have examined the symptoms and effects of Long COVID-19 on other countries' populations. However, there is no published information on the common symptoms and effects of Long COVID-19 among teenagers in Thailand. This study aims to fill that gap by surveying common Long most COVID-19 the symptoms in Thai teenagers. Moreover, this study investigates the effect of this on teenagers' daily lives, and this would be beneficial for the medical profession to cure patients accurately.

#### METHOD

#### Study design

From a survey of Long COVID symptoms of people infected with Covid-19 who are 10-24 years, this survey aims to study about Long COVID symptoms of people who have been infected with Covid-19, Side effects such as prolonged quarantine and complications from drug use, etc. This survey started on May 18, 2022 until May 28, 2022. This survey contains 15 questions which will take approximately 3-5 minutes to complete. This survey reached people who had been infected with Covid-19 mostly through the Line application, and directly through the people they knew who had been Long COVID.

From the survey "The effects of Long COVID on Thai teenagers" 99.526% of respondents agreed to the survey criteria and 0.474% of respondents agreed to the survey criteria. To identify symptoms and other factors that may affect Long COVID symptoms, analysis of this questionnaire was limited to respondents exposed to covid-19 between the ages of 10-24. There were a total of 422 respondents from the questionnaire. A total of 422 responses from Google Forms on May 28, 2022. The following responses have been removed from the dataset. Those who refused to use the data (n=2) and who had never been infected with COVID (n=19), resulted in 401 usable data sets for the respondents which is 93.02% female and male 6.99%. There are 3 age ranges, the age range 10-13 years 3.34%, the age range 14-16 years 26.19%, the age range 17-19 years 51.87%, and the age range 20-24 years 18.70%.

### RESULT

# **1.** General information of sample characteristics

Through their responses on the Google form questionnaire set, 422 Thai teenagers aged 17–24 years old, which were divided into 10–13, 14–16, 17–19, and 20–24, provided online survey data. This data showed the consent of sample characteristics was 99.53%, which was willingly analyzed. Among the sample characteristics, 93.02% were collected from males and 6.98% from females in Thailand. Most of the sample teenagers were 17-19 years old, with 51.87%, and the least occurred at 10-13 years old, with 3.24%.

Table 1. General information of participants		Table 1	. General	information	of	participants.
--	--	---------	-----------	-------------	----	---------------

Variable	Percentage
Overall	100
Consent (n= 422)	
Allow	99.526
Refuse	0.474
Infected with COVID-19 (n=420)	
Ever	95.476
Never	4.524
Gender (n=420)	
Male	6.983
Female	93.017
Age Ranges (year) (n=420)	
10-13	3.242
14-16	26.185
17-19	51.870
20-24	18.703

# 2. Medical information of sample characteristics.

#### 2.1 COVID-19 Vaccination report

The survey found that the vast majority of respondents (74.314%) received 2 doses of the vaccine. Followed by 21.945% of respondents who received 3 doses of vaccine. Later, it was a total number of respondents who received 1 dose of vaccine, accounting for 1.995% and the lowest vaccination history for respondents, accounting for 1.746%, which was not vaccinated.

#### 2.2 Intolerances report of vaccine

The record of drug allergy from a survey of Thai teenagers, there was a drug allergy of 4.630% of respondents and 92.361% of those who were not allergic to coronavirus medication. Drug allergy which were Vancomycin, Andrographis paniculata, Primolut N, Cefuroxime, Penicillin, and Miotin were the least likely 0.231%, while the vast majority of drug allergies were to Amoxicillin and Sulfonamides, the survey showed that there were more drug intolerances than those who are allergic to coronavirus drugs.

#### 2.3 Infect type report

The survey found that the majority of coronavirus cases (60.848%) were infected with unknown strains of coronavirus. Followed by 28.687 % which was infected with the Omicron strain. Lastly, respondents who were infected with the Delta strain COVID-19 accounted for a ratio of 8.229%, and the last one is the respondents who are infected with beta and alpha covids with a ratio of 1.496% and 0.748%, respectively.

#### 2.4 The severity of COVID-19 symptoms

48.130% of respondents were severely affected by COVID-19 symptoms, while moderate COVID-19 symptoms were found in 51.870%.

#### 2.5 Duration of illness

The survey found 72.569% of sample characteristics had a duration of less than a month, 23.691% had been severe in symptoms for one to three months, and respondents were sick for more than 3 months, there are 3.741%. Indicating that

the majority of respondents will have a duration of about 1 month.

#### 2.6 Therapeutic method

The survey found that the majority of coronavirus cases (83.54%) were treated by home isolation, followed by hospitalization at 8.479%. The least part of the ratio of 7.98% is hospital admissions.

#### 2.7 A drug used to treat

According to the survey, the vast majority of coronavirus cases (37.5%) are on symptomatic medication. Following by, the use of Andrographis paniculata with a ratio of 30%. Later, it was the drug Favipiravir accounted for 20.75 percent, and the use of medications received by respondents was the least with a ratio of 11.75%, meaning no medication.

#### 3. Effects of Long COVID-19

### 3.1 Physical health effects after illness

Physical health effects after illness were found that 57.8% of respondents had breathlessness, which was the highest of all effects, 51.4% had fatigue, 26.1% had insomnia and chronic cough, 21.8% had no fault. normal and the remaining effect is less than 1%.

#### **3.2 The effects of prolonged quarantine**

This study found that 37% of sample Thai teenagers had pains and aches which is the highest number of all effects. 31.5% of respondents were depressed and 18.3% were unaffected. Patients who had Clinomania 6.2% and 1.75% had boredom. The remaining effects were less than 1%.

#### 3.3 Level of impact on daily life

The level of impact of COVID-19 on Thai teenagers daily lives in all 10 levels, with the third highest impact level being level 7 representing 15.96%, followed by an equal quantity of level 5 and 6 in the amount of 13.96% and level 3, accounting for 13.46%

#### 3.4 Complications from drug use

Complications from drug use of respondents showed that asymptomatic Thai teenagers accounted for 89.33%, acid reflux was 4.71%, unstable glucose was 1.48%, gastritis was 0.99%, and anorexia accounted for 0.74%.

Variable      Percentage        Overall      100        Vaccination (n=420)      100        Never      1.746        1 dose      1.995        2 doses      74.314        3 doses      21.945        Drug allergy (n=420)      21.945        Not allergic to drugs      4.630        Allergic to drugs      4.630        Amoxicillin      0.926        Vancomycin      0.231        Andrographis paniculate.      0.231        Sulfonamide      0.694        Primolut-N      0.231        Cefuroxime      0.231        Penicillin      0.213        Miotin      0.231        CoVID-19 strain (n=420)      0.231        Unknown      60.848        Omicron      28.678        Delta      8.229        Beta      1.496        Alpha      0.748        Severity of symptoms (n=420)      51.870        Duration of COVID-19 infection (n=420)      51.870        Less than 1 month      72.569        1-3 month      23.691	Table 2. Medical information for COVID patients.			
Vacination (n=420)      1.746        Never      1.995        1 dose      1.995        2 doses      74.314        3 doses      21.945        Drug allergy (n=420)      92.361        Nattergic to drugs      4.630        Amoxicillin      0.926        Vancomycin      0.231        Andrographis paniculate      0.231        Sulfonamide      0.694        Primolut_N      0.231        Cefuroxime      0.231        Penicillin      0.231        Mistin      0.231        CoVID-19 strain (n=420)      0        Unknown      60.848        Omicron      28.678        Delta      8.229        Beta      1.496        Alyre      51.870        Duration of COVID-19 infection (n=420)      51.870        Less than 1 month      72.569        1-3 month      23.691        More than 3 months      3.741        Remedy (n=420)      83.541        Hoogitel (Hotel for cure COVID-19)      84.79	Variable	Percentage		
Never      1.746        1 dose      1.995        2 doses      74.314        3 doses      21.945        Drug allergy (n=420)      74.314        Not allergic to drugs      21.945        Allergic to drugs      4.630        Allergic to drugs      4.630        Amoxicillin      0.926        Vancomycin      0.231        Andrographis paniculate      0.231        Sulfonamide      0.694        Primolut-N      0.231        CoVID-19 strain (n=420)      0.231        Unknown      60.848        Omicron      28.678        Delta      8.229        Beta      1.496        Allpha      0.748        Severity of symptoms (n=420)      51.870        Duration of COVID-19 infection (n=420)      23.691        Less than 1 month      72.569        1-3 month      23.691        More than 3 months      3.741        Remedy (n=420)      83.541        Home isolation      83.541	Overall	100		
1 dose    1.995      2 doses    74.314      3 doses    21.945      Drug allergy (n=420)    92.361      Not allergic to drugs    4.630      Amoxicillin    0.926      Vancomycin    0.231      Sulfonamide    0.694      Princolut-N    0.231      Cefuroxime    0.231      Penicillin    0.231      Mitotin    0.231      COVID-19 strain (n=420)    0.231      Unknown    60.848      Omicron    28.678      Delta    8.229      Beta    1.496      Alpha    0.748      Severity of symptoms (n=420)    51.870      Stightly    48.130      Averagely    51.870      Duration of COVID-19 infection (n=420)    51.870      Less than 1 month    72.569      1-3 month    23.691      More than 3 months    3.741      Remedy (n=420)    83.541      Hoomitel (Hotel for cure COVID-19)    84.79	Vaccination (n=420)			
2 doses  74.314    3 doses  21.945    Drug allergy (n=420)  21.945    Not allergic to drugs  4.630    Amoxicillin  0.926    Vancomycin  0.231    Antrographis paniculate  0.231    Sulfonamide  0.694    Primolut-N  0.231    Cefuroxime  0.231    Penicillin  0.231    Mistin  0.231    COVID-19 strain (n=420)  0.231    Unknown  60.848    Omicron  28.678    Delta  8.229    Beta  1.496    Alipha  0.748    Severity of symptoms (n=420)  51.870    Duration of COVID-19 infection (n=420)  23.691    Less than 1 month  72.569    1-3 month  23.691    More than 3 months  3.741    Remedy (n=420)  83.541    Home isolation  83.541	Never	1.746		
3 doses    21.945      Drug allergy (n=420)    92.361      Allergic to drugs    4.630      Amoxicillin    0.926      Vancomycin    0.231      Andrographis paniculate    0.231      Sulfonamide    0.694      Erimolut-N    0.231      Cefuroxime    0.231      Penicillin    0.231      Miotin    0.231      COVID-19 strain (n=420)    0.231      Unknown    60.848      Omicron    28.678      Delta    8.229      Beta    1.496      Alveragely    51.870      Duration of COVID-19 infection (n=420)    51.870      Less than 1 month    72.569      1-3 month    23.691      More than 3 months    3.741      Remedy (n=420)    83.541      Home isolation    83.541      Home isolation    83.541	1 dose	1.995		
Drug allergy (n=420)      92.361        Not allergic to drugs      4.630        Allergic to drugs      4.630        Amoxicillin      0.926        Vancomycin      0.231        Sulfonamide      0.694        Princolut-N      0.231        Cefuroxime      0.231        Penicillin      0.231        Mitotin      0.231        COVID-19 strain (n=420)      0.231        Unknown      60.848        Omicron      28.678        Delta      8.229        Beta      1.496        Alpha      0.748        Severity of symptoms (n=420)      51.870        Slightly      48.130        Averagely      51.870        Duration of COVID-19 infection (n=420)      51.870        Less than 1 month      72.569        1-3 month      23.691        More than 3 months      3.741        Remedy (n=420)      83.541        Hoogniel (Hotel for cure COVID-19)      84.79	2 doses	74.314		
Not allergic to drugs      92.361        Allergic to drugs      4.630        Amoxicillin      0.926        Vancomycin      0.231        Andtographis paniculate      0.231        Sulfonamide      0.694        Primolut-N      0.231        Cefuroxime      0.231        Penicillin      0.231        Miotin      0.231        Corport      0.231        Corport      0.231        Unknown      0.231        Omicron      28.678        Delta      8.229        Beta      1.496        Alveragely      51.870        Duration of COVID-19 infection (n=420)      51.870        Less than 1 month      72.569        1-3 month      23.691        More than 3 months      3.741        Remedy (n=420)      83.541        Hoogetel (Hotel for cure COVID-19)      84.79	3 doses	21.945		
Allergic to drugs    4.630      Amoxicillin    0.926      Vancomycin    0.231      Andrographis paniculate    0.231      Sulfonamide    0.694      Drimolut-N    0.231      Cefuroxime    0.231      Penicillin    0.231      Miotin    0.231      COVID-19 strain (n=420)    0.231      Unknown    60.848      Omicron    28.678      Delta    8.229      Beta    1.496      Alveragely    51.870      Duration of COVID-19 infection (n=420)    23.691      Less than 1 month    72.569      1-3 month    23.691      More than 3 months    3.741      Remedy (n=420)    83.541      Home isolation    83.541	Drug allergy (n=420)			
Allergic to drugs    4.630      Amoxicillin    0.926      Vancomycin    0.231      Andrographis paniculate    0.231      Sulfonamide    0.694      Drimolut-N    0.231      Cefuroxime    0.231      Penicillin    0.231      Miotin    0.231      COVID-19 strain (n=420)    0.231      Unknown    60.848      Omicron    28.678      Delta    8.229      Beta    1.496      Alveragely    51.870      Duration of COVID-19 infection (n=420)    23.691      Less than 1 month    72.569      1-3 month    23.691      More than 3 months    3.741      Remedy (n=420)    83.541      Home isolation    83.541	Not allergic to drugs	92.361		
Vancomycin      0.231        Andrographis paniculate.      0.231        Sulfonamide      0.694        Primolut.N      0.231        Cefuroxime      0.231        Penicillin      0.231        Mitotin      0.231        CoVID-19 strain (n=420)      0.231        Unknown      60.848        Omicron      28.678        Delta      8.229        Beta      1.496        Alpha      0.748        Severity of symptoms (n=420)      0.748        Stightly      48.130        Averagely      51.870        Duration of COVID-19 infection (n=420)      72.569        1-3 month      23.691        More than 3 months      3.741        Remedy (n=420)      83.541        Home isolation      83.541        Hospitel (Hotel for cure COVID-19)      84.79		4.630		
Andrographis paniculate      0.231        Sulfonamide      0.694        Drimolut-N      0.231        Cefuroxime      0.231        Penicillin      0.231        Miotin      0.231        COVID-19 strain (n=420)      0.231        Unknown      60.848        Omicron      28.678        Delta      8.229        Beta      1.496        Alpha      0.748        Severity of symptoms (n=420)      51.870        Duration of COVID-19 infection (n=420)      23.691        Less than 1 month      72.569        1-3 month      23.691        More than 3 months      3.741        Remedy (n=420)      83.541        Home isolation      83.541	Amoxicillin	0.926		
Sulfonamide      0.694        Drimolut-N      0.231        Cefuroxime      0.231        Penicillin      0.213        Mictin      0.213        COVID-19 strain (n=420)      0.231        Unknown      60.848        Omicron      28.678        Delta      8.229        Beta      1.496        Alpha      0.748        Severity of symptoms (n=420)      51.870        Slightly      48.130        Averagely      51.870        Duration of COVID-19 infection (n=420)      72.569        Less than 1 month      72.569        1-3 month      23.691        More than 3 months      3.741        Remedy (n=420)      83.541        Home isolation      83.541        Hospitel (Hotel for cure COVID-19)      8.479	Vancomycin	0.231		
Primolut N Cefluroxime      0.231        Penicillin      0.231        Victin      0.213        COVID-19 strain (n=420)      0.231        Unknown      60.848        Omicron      28.678        Delta      8.229        Beta      1.496        Alpha      0.748        Severity of symptoms (n=420)      48.130        Slightly      48.130        Averagely      51.870        Duration of COVID-19 infection (n=420)      72.569        1-3 month      23.691        More than 3 months      3.741        Remedy (n=420)      83.541        Home isolation      83.541        Hospitel (Hotel for cure COVID-19)      8.479	Andrographis paniculate	0.231		
Cefuroxime      0.231        Penicillin      0.213        Miotin      0.211        Miotin      0.231        COVID-19 strain (n=420)      0.231        Unknown      60.848        Omicron      28.678        Delta      8.229        Beta      1.496        Alpha      0.748        Severity of symptoms (n=420)      51.870        Duration of COVID-19 infection (n=420)      51.870        Less than 1 month      72.569        1-3 month      23.691        More than 3 months      3.741        Remedy (n=420)      83.541        Home isolation      83.541        Hospitel (Hotel for cure COVID-19)      8.479	Sulfonamide	0.694		
Penicillin      0.213        Mistin      0.231        COVID-19 strain (n=420)      0.231        Unknown      60.848        Omicron      28.678        Delta      8.229        Beta      1.496        Alpha      0.748        Severity of symptoms (n=420)      51.870        Slightly      48.130        Averagely      51.870        Duration of COVID-19 infection (n=420)      72.569        Less than 1 month      72.569        1-3 month      3.741        Remedy (n=420)      83.541        Home isolation      83.541        Hospitel (Hotel for cure COVID-19)      8.479	Primolut-N	0.231		
Miotin      0.231        COVID-19 strain (n=420)      0.0231        Unknown      60.848        Omicron      28.678        Delta      8.229        Beta      1.496        Alpha      0.748        Severity of symptoms (n=420)      48.130        Slightly      48.130        Averagely      51.870        Duration of COVID-19 infection (n=420)      72.569        1-3 month      23.691        More than 3 months      3.741        Remedy (n=420)      83.541        Home isolation      83.541        Hospitel (Hotel for cure COVID-19)      8.479	Cefuroxime	0.231		
COVID-19 strain (n=420)      60.848        Unknown      60.848        Omicron      28.678        Delta      8.229        Beta      1.496        Alpha      0.748        Severity of symptoms (n=420)      51.870        Duration of COVID-19 infection (n=420)      23.691        Less than 1 month      72.569        1-3 month      23.691        More than 3 months      3.741        Remedy (n=420)      83.541        Home isolation      83.541        Hospitel (Hotel for cure COVID-19)      8.479	Penicillin	0.213		
Unknown      60.848        Omicron      28.678        Delta      28.678        Beta      1.496        Alpha      0.748        Severity of symptoms (n=420)      8.130        Slightly      48.130        Averagely      51.870        Duration of COVID-19 infection (n=420)      72.569        I-3 month      23.691        More than 3 months      3.741        Remedy (n=420)      83.541        Home isolation      83.541        Hospitel (Hotel for cure COVID-19)      8.479	Miotin	0.231		
Omicron      28.678        Delta      8.229        Beta      1.496        Alpha      0.748        Severity of symptoms (n=420)      48.130        Slightly      48.130        Averagely      51.870        Duration of COVID-19 infection (n=420)      72.569        1-3 month      23.691        More than 3 months      3.741        Remedy (n=420)      83.541        Home isolation      83.541        Hospitel (Hotel for cure COVID-19)      8.479	COVID-19 strain (n=420)			
Delta      8.229        Beta      1.496        Alpha      0.748        Severity of symptoms (n=420)      8.130        Slightly      48.130        Averagely      51.870        Duration of COVID-19 infection (n=420)      72.569        1-3 month      23.691        More than 3 months      3.741        Remedy (n=420)      83.541        Home isolation      83.541        Hospitel (Hotel for cure COVID-19)      8.479	Unknown	60.848		
Beta      1.496        Alpha      0.748        Severity of symptoms (n=420)      48.130        Slightly      48.130        Averagely      51.870        Duration of COVID-19 infection (n=420)      72.569        Less than 1 month      23.691        1-3 month      3.741        Remedy (n=420)      83.541        Home isolation      83.541        Hoogrief (Hotel for cure COVID-19)      8.479	Omicron	28.678		
Alpha      0.748        Severity of symptoms (n=420)      48.130        Slightly      48.130        Averagely      51.870        Duration of COVID-19 infection (n=420)      72.569        Less than 1 month      23.691        1-3 month      3.741        Remedy (n=420)      83.541        Home isolation      83.541        Hospitel (Hotel for cure COVID-19)      8.479	Delta	8.229		
Severity of symptoms (n=420)      48.130        Slightly      48.130        Averagely      51.870        Duration of COVID-19 infection (n=420)      72.569        1-3 month      72.569        More than 3 months      3.741        Remedy (n=420)      83.541        Home isolation      83.541        Hospitel (Hotel for cure COVID-19)      8.479	Beta	1.496		
Slightly      48.130        Averagely      51.870        Duration of COVID-19 infection (n=420)      72.569        Less than 1 month      23.691        1-3 month      23.691        More than 3 months      3.741        Remedy (n=420)      83.541        Home isolation      83.541        Hospitel (Hotel for cure COVID-19)      8.479		0.748		
Averagely      51.870        Duration of COVID-19 infection (n=420)      72.569        Less than 1 month      23.691        1-3 month      3.741        Remedy (n=420)      83.541        Home isolation      83.541        Hospitel (Hotel for cure COVID-19)      8.479	Severity of symptoms (n=420)			
Duration of COVID-19 infection (n=420)      72.569        1-3 month      23.691        More than 3 months      3.741        Remedy (n=420)      83.541        Home isolation      83.541        Hospitel (Hotel for cure COVID-19)      8.479	Slightly	48.130		
Less than 1 month      72.569        1-3 month      23.691        More than 3 months      3.741        Remedy (n=420)      83.541        Home isolation      83.541        Hospitel (Hotel for cure COVID-19)      8.479		51.870		
1-3 month      23.691        More than 3 months      3.741        Remedy (n=420)      83.541        Home isolation      83.541        Hospitel (Hotel for cure COVID-19)      8.479				
More than 3 months      3.741        Remedy (n=420)      83.541        Home isolation      83.541        Hospitel (Hotel for cure COVID-19)      8.479		72.569		
Remedy (n=420)Home isolation83.541Hospitel (Hotel for cure COVID-19)8.479	1-3 month	23.691		
Home isolation 83.541 Hospitel (Hotel for cure COVID-19) 8.479		3.741		
Hospitel (Hotel for cure COVID-19) 8.479	Remedy (n=420)			
Hospital 7.980				
	Hospital	7.980		
Drugs used (n=420)				
Naturopathy 11.750				
Andrographis paniculate. 30.000				
Favipiravir 20.750				
Symptomatic treatment 37.500	Symptomatic treatment	37.500		

Table 2	Madical	information	for	COVID	notionto
1 able 2.	Medical	information	IOL	COVID	patients.

#### Table 3. Effects of Long COVID-19

Variable	Percentage
Overall	100
The effects of prolonged quarantine (n=420)	
Asymptomatic	31.774
Depression	19.299
Stick to bed	6.238
Pressure sores	0.390
Aches	37.037
Debility	0.975
Boring	1.754
Coughing	0.585
Runny nose	0.390
Sore throat	0.585
Uncomfortable	0.195
Anorexia	0.195
Dizzy	0.195
Tachyphemia	0.195
Diarrhea	0.195
Drug-related complications (n=420)	
Asymptomatic	89.578
Stomach ache	0.993
Gastroesophageal reflux disease	4.715
Unstable sugar	1.489
Aphthous stomatitis	0.248
Bitter in the mouth	0.248
Anorexia	0.744
Eyes turn to blue	0.248
Suffocate	0.248
Puffy face	0.248
Vaginal Discharge	0.248
Sore throat	0.248
Oversleep	0.248
Head ache	0.248
Diarrhea	0.248

Physical health effects (n=420)	
Asymptomatic	8.908
Asthma	30.615
Debility	27.227
Fibrotic-Interstitial Lung Disease	0.125
Heart disease	1.004
Thrombosis	0.125
Sepsis	0.125
Sleepless	11.543
Chronic cough	13.802
Loss of taste	2.384
When coughing, they smell the blood.	0.125
Head ache	0.251
Anorexia	0.125
Forgetful	0.251
Sweating during sleep	0.125
Voice changed	0.251
Sore throat	0.376
Dizzy	0.627
Hair loss	0.753
Loss of smell	0.753
Hay fever	0.125
Rash	0.251
Missed Period	0.125
Level of impact on daily life (1 - 10) (n=420)	
1	2.244
2	6.983
3	13.466
4	11.970
5	13.965
6	13.965
7	15.960
8	10.474
9	3.990
10	6.983

#### DISCUSSION

In this study, the researcher discussed the research findings in relation to the research objectives as follows: Our study discovered that most COVID-19 patients experienced pain and aches as a result of prolonged quarantine (Table 3). As our study explored, the majority of the surveyed Thai teenagers who received two doses of vaccine (Table 2) were free of allergy to the drugs used to cure coronavirus (Table 2). However, the majority of respondents we surveyed did not know what strain of coronavirus they were infected with (Table 2). The majority of Thai teenagers surveyed had moderate to severe symptoms (Table 2) and had been infected for less than one month (Table 2). They were placed in home isolation (Table 2) and given symptomatic medication (Table 2). The majority of them had difficulty breathing after being infected with COVID-19 (Table 3). The limitations of our study Studies have different methods of collecting data. Answers to online questionnaires may affect the overall outcome of the study. Especially since online questionnaires often overestimate the level of information.

#### CONCLUSION

This study aims to examine the long-term COVID-19 symptoms that frequently occur

in Thai teenagers. The current research shows that most people have dyspnea, debility, and chronic cough after being infected by COVID-19. .Moreover, this study also provides information on the effect of curing by medicine and quarantining: this pandemic usually affects their mental health more than their physical health during the treatment period and after recovering from COVID-19. Importantly, teenagers ranked the level of effect this pandemic has had on their daily lives at 7 out of 10. Therefore, these findings clarify most common Long COVID-19 the symptoms and their effects on people: Physical health and mental health. Being able to correctly treat patients would help the medical field.

#### Acknowledgement

This study was made possible by the assistance of notable individuals who directed and assisted the Researchers during the execution of this investigation. Their sincere appreciation goes to the people who assisted them in expanding their perspectives during this research.

From the moment they began the study until it was finished, their parents patiently provided them with financial, mental, and spiritual support. The encouragement they received encouraged them to continue what they had begun. They also want to thank them for their continuous tolerance and persistent inspiration.

First and foremost, they owed a debt of gratitude to their friends, who have helped them persevere by encouraging them whenever they felt down and pushing them to accomplish and submit their research by the date.

## Conflict of Interest: None

#### Source of Funding: None

#### REFERENCE

- Crook, H., Raza, S., Nowell, J., Young, M., & Edison, P. (2021). Long covidmechanisms, risk factors, and management. BMJ, 374, n1648. doi:10.1136/bmj.n1648
- Fainardi, V., Meoli, A., Chiopris, G., Motta, M., Skenderaj, K., Grandinetti, R., . . . Esposito, S. (2022). Long COVID in Children and Adolescents. Life (Basel), 12(2). doi:10.3390/life12020285
- 3. Hammami, A., Harrabi, B., Mohr, M., & Krustrup, P. (2020). Physical activity and coronavirus disease 2019 (COVID-19): specific recommendations for home-based physical training. Managing Sport and Leisure, 27(1-2), 26-31. doi:10.1080/23750472.2020.1757494
- Katewongsa, P., Widyastaria, D. A., Saonuam, P., Haematulin, N., & Wongsingha, N. (2021). The effects of the COVID-19 pandemic on the physical activity of the Thai population: Evidence from Thailand's Surveillance on Physical Activity 2020. J Sport Health Sci, 10(3), 341-348. doi:10.1016/j.jshs.2020.10.001
- Lateh, A., Pasunon, P., Dolah, K., Kongjam, P., Chemae, S., Panomwan, P., & Lateh, A. (2021). COVID-19 Preparedness and the

Anxiety of Thai Citizens. Kesmas: National Public Health Journal, 16(3). doi:10.21109/kesmas.v16i3.4375

- Prevention, C. f. D. C. a. (2022). COVID-19: Symtoms. Retrieved from https://www.cdc.gov/coronavirus/2019ncov/symptomstesting/symptoms.html?fbclid=IwAR2wmm uNnAS4iVT3Ud4RbxIjaHcjo08UJtP6Xghz DQcujFlRyGFduoLr-MI
- Publishing, H. H. (2022). Symptoms, spread and other essential information about the coronavirus and COVID-19. Retrieved from https://www.health.harvard.edu/diseasesand-conditions/covid-19basics?fbclid=IwAR2wtu9\_uZklV6XopPZ4 hh-xSKftJNiS8mr6MfYa-J-81by01r5SYDSVhck
- 8. Services, D. o. M. Long Covid: the symptoms and tips for recovery.
- Sivan, M., & Taylor, S. (2020). NICE guideline on long covid. BMJ, 371, m4938. doi:10.1136/bmj.m4938
- Tang, X., Wu, C., Li, X., Song, Y., Yao, X., Wu, X., . . . Lu, J. (2020). On the origin and continuing evolution of SARS-CoV-2. Natl Sci Rev, 7(6), 1012-1023. doi:10.1093/nsr/nwaa036
- Taribagil, P., Creer, D., & Tahir, H. (2021).
  'Long COVID' syndrome. BMJ Case Rep, 14(4). doi:10.1136/bcr-2020-241485
- 12. William Ericson-Neilsen, M. A. D. K., MD, PhD. <Steroids Pharmacology, Complications, and Practice Delivery Issues.pdf>.

How to cite this article: Chantisa Boontia, Jarut Wongwachirapan, Nalinnipha Kaewsuwan et.al. The effects of long COVID on Thai teenagers. International Journal of Science & Healthcare Research. 2022; 7(3): 320-326. DOI: https:// doi.org/10.52403/ ijshr.20220744

\*\*\*\*\*